Graft Versus Host Disease (GvHD) Treatments
Find Graft Versus Host Disease (GvHD) Treatments
Brand Name
Niktimvo
Generic Name
Axatilimab-Csfr
View Brand Information FDA approval date: August 14, 2024
Classification: Colony Stimulating Factor-1 Receptor Blocker
Form: Injection
What is Niktimvo (Axatilimab-Csfr)?
NIKTIMVO is indicated for the treatment of chronic graft-versus-host disease after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg. NIKTIMVO is a colony stimulating factor-1 receptor -blocking antibody indicated for the treatment of chronic graft-versus-host disease after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg.
Approved To Treat
Top Global Experts
There are no experts for this drug
Save this treatment for later
Not sure about your diagnosis?
Tired of the same old research?
Related Clinical Trials
There is no clinical trials being done for this treatment